<DOC>
	<DOC>NCT00420303</DOC>
	<brief_summary>To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.</brief_summary>
	<brief_title>Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion criteria Spondylarthropathy Heel enthesitis refractory to standard treatment Between 18 and 70 years of age The patient global assessment of the disease activity (measured by a 100 mm VAS) must be &gt;40 in the last 48 hours Exclusion criteria Use of &gt; 1 local steroid injection within 2 weeks of screening Prior exposure to any TNFinhibitor, including etanercept Dose of NSAIDs changed within two weeks of study drug evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Refractory Heel Enthesitis in Spondylarthropathy</keyword>
	<keyword>Spondylarthropathy</keyword>
	<keyword>Refractory Heel Enthesitis</keyword>
</DOC>